About 700 reports

The drug claimed blockbuster status just one year after its launch.

  • Drug Development
  • Pharmaceutical
  • Therapy
  • Company
  • Market Size
  • Top Indications for CNS
  • MS Trials as a Percent of CNS Trials

PIPELINE PRODUCTS - REGIONAL BREAKDOWN - - - - - - - - - - - - - - - - - - - - - - - - - Stage US Europe Japan Canada Global Pre-Registration ## ## Filing Rejected/ Withdrawn ## ## Phase III ## ## ## ## Phase II ## ## ## Phase I ## ## ## ## Phase ## IND/ CTA Filed Precl

  • Drug Development
  • United States
  • Biogen Idec Inc.
  • Novartis AG
  • Sanofi S.A.
  • 7.6.3 SAFETY
  • FREQUENTLY REPORTED AES DURING A PHASE III CLINICAL TRIAL COMPARING AZOPT, TRUSOPT, AND

HIGH PREVALENCE OF ANXIETY AND DEPRESSION IN PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA.

  • Drug Development
  • Aerie Pharmaceuticals, Inc.
  • Alcon, Inc.
  • Allergan plc
  • Santen Pharmaceutical Co., Ltd.

India ##.

  • Drug Development
  • World
  • Biogen Idec Inc.
  • Eisai Co., Ltd.
  • Roche Group
  • CLINICAL TRIAL INITIATE IN Q3 2018 BY GEOGRAPHY, GLOBAL
  • CRO Activity in 2018 (Q3)

PLoS One; ##(##): e##.

  • Drug Development
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.

OTHER COMMON AES INCLUDE DIZZINESS, DEPRESSION, SHORTNESS OF BREATH, BRADYCARDIA, HYPOTENSION, DIARRHEA, PRURITUS, AND RASH.

  • Drug Development
  • Interventional Cardiology Device
  • Market Size
  • Bristol-Myers Squibb Company
  • Les Laboratoires Servier SAS

Depression and mood indicators in newly diagnosed glaucoma patients.

  • Drug Development
  • Adverum Biotechnologies, Inc.
  • Alcon, Inc.
  • Allergan plc
  • Astellas Pharma Inc.

IN ADDITION, ONE IN FIVE MEN WITH PCA HAS BEEN REPORTED TO EXPERIENCE DEPRESSION, WITH HALF OF THOSE MEN EXPERIENCING " SEVERE" DEPRESSION (HEIM AND OEI, 1993). ## Epidemiology ##. ## DISEASE BACKGROUND PCA IS A MALIGNANCY IN THE PROSTATE GLAND, WHICH IS LOCATED BELOW

  • Drug Development
  • Hospital
  • Therapy
  • United States
  • PROVENGE group
  • 12.7.4 MNM VIEW

It is also working on a complementary genomic depression test that does not require FDA approval.

  • Drug Development
  • Healthcare
  • World
  • Market Size
  • Cogstate Limited
  • 12.7.4 MNM VIEW

It is also working on a complementary genomic depression test that does not require FDA approval.

  • Drug Development
  • Healthcare
  • World
  • Market Size
  • Cogstate Limited
  • BIPOLAR DISORDER (MANIC DEPRESSION) THERAPEUTICS, G7 COUNTRIES, CLINICAL TRIALS BY PHASE, 2018*
  • BIPOLAR DISORDER (MANIC DEPRESSION) THERAPEUTICS, GLOBAL, CLINICAL TRIALS BY REGION (%), 2018*

BIPOLAR DISORDER (MANIC DEPRESSION) THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* BIPOLAR DISORDER (MANIC DEPRESSION) THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2018* BIPOLAR DISORDER (MANIC DEPRESSION) THERAPEUTICS CLINICAL TRIALS,

  • Clinical Trial
  • Depression
  • Drug Development
  • Neurology
  • World

The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study.

  • Drug Development
  • Market Size
  • AbbVie Inc.
  • Janssen Biotech, Inc.
  • Novartis AG

According to Office of National Statistics, one in every four UK citizens are affected with depression.

  • Drug Development
  • Pain Relief
  • World
  • Forecast
  • Allergan plc
  • TREATMENT RESISTANT DEPRESSION THERAPEUTICS, G7 COUNTRIES, CLINICAL TRIALS BY TRIAL STATUS, 2018*
  • TREATMENT RESISTANT DEPRESSION THERAPEUTICS, E7 COUNTRIES, CLINICAL TRIALS BY PHASE, 2018*

TREATMENT RESISTANT DEPRESSION THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* CLINICAL TRIALS BY PHASE IN E## COUNTRIES TREATMENT RESISTANT DEPRESSION THERAPEUTICS, E## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* TREATMENT RESISTANT DEPRESSION THERAPEUTICS, E## CO

  • Clinical Trial
  • Depression
  • Drug Development
  • World
  • Product Initiative

The role of depression in the context of chronic pain conditions such as neuropathic pain is complex, as it is thought that depression can increase the subjective experience of pain and its debilitating effects.

  • Drug Development
  • Market Size
  • Allergan plc
  • Amgen Inc.
  • Depomed, Inc.

PloS one; ##(##): e##, ##-## Montouris G, et al. (2015).

  • Drug Development
  • Mental Health
  • Market Size
  • Eisai Co., Ltd.
  • GW Pharmaceuticals plc
  • CLINICAL TRIALS - THERAPY AREA PERSPECTIVE
  • CLINICAL TRIALS - ENROLLMENT ANALYTICS

Out of these, one drug is in Phase III, four drugs are in Phase II, and one drug is being developed in Phase I.

  • Drug Development
  • Allergan plc
  • Eisai Co., Ltd.
  • Novartis AG
  • Roche Group

Acne Vulgaris and Depression: A Retrospective Examination.

  • Drug Development
  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.
  • Apricus Biosciences, Inc.

Rare AEs include hepatitis, depression and temporary male infertility.

  • Drug Development
  • Market Size
  • AbbVie Inc.
  • Galapagos NV
  • Pfizer Inc.

As the disease progresses, non-motor symptoms such as depression and sleeping disorders may also develop.

  • Drug Development
  • Biogen Idec Inc.
  • Novartis AG
  • Roche Group
  • Sanofi S.A.
  • Selected clinical trials of lamotrigine in bipolar depression
  • Vraylar late-phase clinical trials as a therapy in bipolar depression

Patients must have also experienced one or more episodes of major depression lasting for two weeks.

  • Drug Development
  • North America
  • United States
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • 16.2.6 TRANS GENIC, INC.
  • Patent

The company received USD ## million from Dennis J.

  • Drug Development
  • Charles River Laboratories International, Inc.
  • genOway SA
  • Horizon Discovery
  • Taconic Biosciences, Inc.

Depression and Anxiety Disorders among Patients with Psoriasis: A Hospital-Based Case-Control Study.

  • Drug Development
  • AbbVie Inc.
  • Eli Lilly & Co.
  • Janssen Biotech, Inc.
  • Johnson & Johnson

Immunotherapy; ##(##): ##-##.

  • Drug Development
  • Market Size
  • Actelion Ltd
  • Bristol-Myers Squibb Company
  • Pfizer Inc.

In addition, neurological deficits are extremely common after stroke and play a large role in survivability and quality of life - depression is also common.

  • Drug Development
  • Interventional Cardiology Device
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

These severe AEs included confusion and shortness of breath, altered mental status and depression, and hypomagnesemia.

  • Drug Development
  • Market Size
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

ONE UNIT REFERS TO ONE ML.

  • Drug Development
  • Latin America
  • Mexico
  • North America
  • Forecast

ONE UNIT REFERS TO ONE ML.

  • Drug Development
  • Eastern Europe
  • Russia
  • Forecast
  • bioMerieux S.A.

Scale = ## to ##, where ## is low impact & ## is high impact.

  • Drug Development
  • Interventional Cardiology Device
  • Boston Scientific Corporation
  • Cordis Corporation
  • Medtronic, Inc.

DKA is more common in T##DM than T##DM, and results from differential glucose metabolism, producing acidic ketone bodies that can cause coma due to alterations in blood pressure producing CNS depression.

  • Drug Development
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Eli Lilly & Co.
  • Johnson & Johnson